Released Mar 27, 2014, after the close
10-K filed Mar 31, 2014, 90 days after period end · 0001019687-14-001135
Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.58M$6.58M derived+10.8% vs Q4 2012+19.0% vs Q3 2013
Net Income-$351.00K-$351.00K derivedN/M vs Q4 2012N/M vs Q3 2013
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$402,000N/M
Operating Cash Flowderived$672,000−42.2%
Free Cash Flowderived-$13,000N/M
Margins · derived
Operating margin-6.1%−14.2 pt vs Q4 2012
Net margin-5.3%−15.9 pt vs Q4 2012
What the release said
The release
Same quarter
| Metric | Q4 2013dderived from reported figures | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $6.58M | $5.93M | $6.10M | — |
| Net Income | -$351.00K | $629.00K | -$1.04M | — |
| EPS Diluted | — | $0.01 | -$0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR